Jesse Treu Insider Profile
4 Followers
Jesse Treu, Director at Aldeyra Therapeutics, holds 1.89M shares in Aldeyra Therapeutics (Ticker: ALDX), holds 1.23M shares in Veracyte (Ticker: VCYT), holds 32.09K shares in Tobira Therapeutics (Ticker: TBRA). Most recently, Jesse Treu Sold ― shares of Aldeyra Therapeutics on Mar 28, 2019 for an estimated value of $968.40K.
Jesse Treu's Trading History
| ALDXAldeyra Therapeutics | Mar 28, 2019 | Director | Informative Sell | 968.40K | $1.21M | |
| VCYTVeracyte | Mar 04, 2019 | Director | Informative Sell | 21.43M | $30.05M | |
| CADXCadence Pharma | Mar 21, 2014 | ― | Uninformative Sell | 146.20M | ― | |
| AKAOQAchaogen | Mar 17, 2014 | ― | Uninformative Buy | ― | $847.25 | |
| DRNADicerna Pharma | Feb 04, 2014 | ― | Uninformative Buy | 296.76K | $497.01K | |
| EVOKEvoke Pharma | Sep 30, 2013 | ― | Uninformative Buy | ― | $266.82K | |
| TBRATobira Therapeutics | Aug 28, 2013 | ― | Uninformative Buy | ― | $1.35M | |
| OCRXOcera Therapeutics | Jul 15, 2013 | ― | Informative Buy | 7.99M | $6.31M | |
| ESPREsperion | Jul 02, 2013 | ― | Uninformative Buy | ― | $112.10K | |
| ~ACHNAchillion Pharmaceuticals | Jan 18, 2013 | ― | Uninformative Sell | ― | $1.65M | |
| CLPMCelator Pharmaceuticals | Jan 14, 2013 | ― | Informative Buy | ― | $67.88M | |
| DRTXDurata | Jul 24, 2012 | ― | Uninformative Buy | ― | ― | |
| OREXQOrexigen | Dec 22, 2011 | ― | Informative Buy | 680.26K | $253.22 | |
| CLVSQClovis Oncology | Nov 21, 2011 | ― | Uninformative Buy | ― | $765.20 | |
| ZGNXZogenix | Sep 20, 2011 | ― | Informative Buy | 7.00M | $4.52M | |
| ALIMAlimera | Jun 03, 2011 | ― | Uninformative Sell | ― | $225.98K | |
| PRTKParatek Pharmaceuticals | Jan 30, 2009 | ― | Informative Sell | 238.75K | $151.36K | |
| VOLCVolcano Corp | ― | ― | ― | ― | ||
| SOMXSomaxon Pharmaceuticals | ― | ― | ― | ― | ||
| SNTSSantarus | ― | ― | ― | ― | ||
| VNDAVanda | ― | Ten Percent Owner | ― | $84.06K | ||
| SNMXSenomyx | ― | ― | ― | $91.18K | ||
| NUVANuVasive | ― | ― | ― | $318.00K | ||
| CLCDCoLucid Pharmaceuticals | ― | ― | ― | $0.00 | ||
| TNDMTandem Diabetes Care | ― | Director, Ten Percent Owner | ― | $0.00 |
You May Also Like
Jesse Treu insider profile FAQ
What is the percentage of profitable transactions made by Jesse Treu?
The percentage of profitable transactions made by Jesse Treu is 50%.
What is the average return per transaction made by Jesse Treu?
The average return per transaction made by Jesse Treu is -11.10%.
What stocks does Jesse Treu hold?
Jesse Treu holds: ALDX, TBRA, VCYT, TNDM, CLCD, OCRX, CLVSQ, CLPM, ZGNX, ~ACHN, ESPR, NUVA, SNMX, VNDA, AKAOQ, DRNA, OREXQ, ALIM, EVOK, CADX, SNTS, SOMX, PRTK, VOLC, DRTX stocks.
What was Jesse Treu’s latest transaction?
Jesse Treu’s latest transaction was an Informative Sell of $968.40K.
What was Jesse Treu's most profitable transaction?
Jesse Treu’s most profitable transaction was an Informative Sell of ALDX stock on March 28, 2019. The return on the trade was 72.60%.
What is Jesse Treu's role in Aldeyra Therapeutics?
Jesse Treu's role in Aldeyra Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
